Rick has helped bring transformative medicines to patients in more than 10 diseases across multiple successful biotech companies. Before joining Affinia Therapeutics, Rick was Chief Business Officer at AveXis where he played a significant role in the company’s build and sale to Novartis for $8.7 billion and the launch of Zolgensma®, its flagship gene therapy product. Prior to AveXis, Rick was Chief Business Officer at Catabasis Pharmaceuticals and before that, a Senior Vice President in the commercial group at InterMune until its acquisition by Roche. Before this, Rick held roles of increasing responsibility at MedImmune (AstraZeneca) and at Centocor (J&J). Before joining the industry, Rick practiced as a clinical pharmacist in a hospital setting. He received his B.S. in Pharmacy from the University of Iowa and his M.B.A. from the Wharton School.